IP Library Granted Patent US 11,484,510
Granted Patent B2
US 11,484,510 · App. 16/106,591 · Granted Nov 1, 2022

Method to treat vitiligo

Inventors: Lekhram Changoer (Ridderkerk, NL); George Anastassov (New York, NY)
Assignee: APIRx Pharmaceutical USA, LLC
A61K31/05A61K9/0014A61K31/201A61K31/352A61K31/728A61K36/24A61K36/58A61K36/74A61K36/9066A61P17/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,484,510
App. No.
16/106,591
Granted
Nov 1, 2022
Kind
B2
Abstract

A method to treat the skin condition vitiligo is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol, at a concentration of 3%-20% by weight of the composition onto the affected skin area of a subject in need thereof. Application may be twice (2) daily for about six (6) weeks. Cannabidiol and cannabigerol may be sourced naturally or synthetically.

Claims (13)

1. A method of treating vitiligo in a human in need thereof consisting essentially of topically administering to the human in need thereof about 15 wt. % of cannabidiol and cannabigerol, wherein the human is administered low or trace amounts of Δ 9 tetrahydrocannabinol and wherein the cannabigerol is present at a twice to three times the weight of the cannabidiol.

2. The method of claim 1 , wherein the cannabidiol and cannabigerol are from a natural source.

3. The method of claim 1 , wherein the cannabidiol and cannabigerol are synthetic.

4. The method of claim 1 , wherein the cannabidiol and cannabigerol are in powder form prior to use.

5. The method of claim 1 , wherein the cannabidiol and cannabigerol are in crystalline form prior to use.

6. The method of claim 1 , wherein the cannabidiol and cannabigerol are microencapsulated.

7. The method of claim 1 , wherein the cannabidiol and cannabigerol are nanoencapsulated with particle sizes of 20 nanometers to 40 nanometers.

8. The method of claim 1 , wherein the cannabidiol and cannabigerol further consists essentially of sodium oleyl hyaluronate.

9. The method of claim 1 , wherein the cannabidiol and cannabigerol further consist of at least one of omega-3 fatty acids or omega-6 fatty acids.

10. The method of claim 1 , wherein the cannabidiol and cannabigerol further consist essentially of neem extract, Curcuma longa extract, rubia cardifolia extract, or wrightia tinctorial extract.

11. The method of claim 1 , wherein the cannabidiol and cannabigerol further consist essentially of cacao butter.

12. The method of claim 1 , wherein the cannabidiol and cannabigerol are in a hydro gel form, a liquid form, a spray form, a powder form, or an ointment form.

13. The method of claim 1 , wherein the cannabidiol and cannabigerol are applied twice daily for six weeks onto the affected skin areas of a human suffering from vitiligo.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2020
From: AXIM BIOTECHNOLOGIES, INC.
To: APIRX PHARMACEUTICAL USA, LLC
Reel/Frame 052752/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2018
From: CHANGOER, LEKHRAM; ANASTASSOV, GEORGE
To: AXIM BIOTECHNOLOGIES, INC.
Reel/Frame 046819/0848 →
Continuity (2)
Provisional Application 62550885 · Aug 28, 2017
Related Publication 20190060252A1 · Feb 28, 2019